CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Hydroxychloroquine Sulfate Tablets +1 moredrug
Likely dose
Hydroxychloroquine Sulfate Tablets 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02874287
NCT02874287Phase 4Completed
CompareCT.gov

Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.

First Affiliated Hospital Xi'an Jiaotong University·interventional·Posted Aug 22, 2016·Updated Aug 27, 2021

In Brief

A Phase 4 clinical trial evaluating Hydroxychloroquine Sulfate Tablets and Placebo Tablets for Coronary Artery Disease. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate whether treated with hydroxychloroquine could improve therapeutic effect for patients with high-risk coronary artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 22, 2016
Enrollment StartOct 8, 2017
Primary CompletionMar 1, 2019
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago

Interventions

Hydroxychloroquine Sulfate Tabletsdrug

Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.

Placebo Tabletsdrug

Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.